ASCO-GU 2025

AVENANCE real-world study of avelumab first-line (1L) maintenance treatment for advanced urothelial carcinoma (UC): analyses in low tumor burden subgroups

Barthélémy P, et al.

Molecular subtypes, NECTIN4/HER2 expression, and clinical outcomes in patients with advanced urothelial carcinoma or muscle invasive bladder cancer: Exploratory analyses from JAVELIN Bladder 100 and the Tempus database

Eckstein M, et al. 

Real-world effectiveness and safety of avelumab first-line maintenance (1LM) treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): second interim analysis of the AVENUE study

Goebell PJ, et al.

Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): long-term outcomes from JAVELIN Bladder 100

Gupta S, et al.

Avelumab first-line (1L) maintenance therapy in advanced urothelial carcinoma: final analysis from a real-world study in the UK

Jones RJ, et al.

Avelumab in combination with axitinib for the first-line treatment of advanced renal cell carcinoma (aRCC): a systematic literature review of real-world effectiveness and safety

Kearney M, et al.

Patient and caregiver preferences for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC): results of a targeted literature review (TLR)

Kearney M, et al.

Patient-reported outcome (PRO) assessment and reporting in first-line (1L) locally advanced or metastatic urothelial cancer (la/mUC) clinical trials: Results of a systematic literature review (SLR)

Kearney M, et al.

Real-world effectiveness and treatment (tx) patterns in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in Japan: results from the JAVEMACS chart review study

Kitamura H, et al.

Nectin-4 RNA expression and clinical outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC): Exploratory analyses from JAVELIN Bladder 100

Klümper N, et al.

Evaluation of avelumab first-line maintenance therapy and subsequent treatment in patients with locally advanced or metastatic urothelial carcinoma using a large claims database in Japan: JAVEMACS-D

Kobayashi T, et al.

Real-world effectiveness and safety of first-line (1L) avelumab + axitinib in patients with advanced renal cell carcinoma (aRCC): primary analysis of the AVION study

Merseburger AS, et al.

Patient profiles as drivers of physicians’ treatment choice in the first-line treatment of locally advanced or metastatic urothelial cancer (la/mUC): Perspectives from a US study

Milloy N, et al.

Impact of tumor burden on treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) treated with avelumab first-line maintenance (1LM)

Moon HH, et al.

Avelumab maintenance therapy in patients (pts) with advanced urothelial carcinoma (UC) in Japan: subgroup analyses by prior chemotherapy regimen from post-marketing surveillance (PMS)

Nagata M, et al.

Real-world safety of first-line (1L) therapies for locally advanced or metastatic urothelial cancer (la/mUC) in the US

Nizam A, et al.

Patterns of split-dose gemcitabine and cisplatin (GC) use in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): results of a 10-country physician survey

O'Dwyer R, et al.

Avelumab first-line (1L) maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: updated real-world results from a national reimbursement registry

Študentová H, et al.